Sign In
Buy AXGN
$40.63
+1.17 (+2.97%)
At Close: Jun 03, 2026
The Daily Biotech Pulse: Novavax Vaccine Data, Aerpio Gets $5.1M Funding For COVID Trial, Rigel Gains Big On Earnings
12:00am, Wednesday, 05'th Aug 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)
ABIOMED, Inc. (NASDAQ: ABMD) (FDA approved the emergency use of Abiomed's Impella heart pump in combination...
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
12:00am, Sunday, 02'nd Aug 2020
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
Earnings Preview: AxoGen (AXGN) Q2 Earnings Expected to Decline
04:33pm, Wednesday, 29'th Jul 2020
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axogen, Inc. to Present at the Canaccord Genuity 40th Annual Growth Conference
11:00am, Wednesday, 29'th Jul 2020
ALACHUA, Fla., July 29, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves
BioNTech COVID-19 Progress, And Other News: The Good, Bad And Ugly Of Biopharma
10:43am, Thursday, 23'rd Jul 2020
BioNTech reports positive COVID-19 vaccine data with Pfizer, receives $2 billion order from US Govt. AxoGen completes enrollment in pivotal nerve graft study.
Axogen RECON Clinical Study Completes Target Enrollment of 220 Subjects
11:00am, Wednesday, 22'nd Jul 2020
RECON is a pivotal study supporting the Company’s Biologics License Application (BLA) for Avance® Nerve GraftALACHUA, Fla., July 22, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global l
Axogen, Inc. to Report Second Quarter 2020 Financial Results and Host Conference Call on August 5, 2020
11:00am, Wednesday, 15'th Jul 2020
ALACHUA, Fla., July 15, 2020 -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral.
Is AxoGen, Inc. (AXGN) Going to Burn These Hedge Funds?
10:41pm, Wednesday, 08'th Jul 2020
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and succes
Squarepoint Ops LLC Makes New $200,000 Investment in AxoGen, Inc (NASDAQ:AXGN)
06:40am, Wednesday, 08'th Jul 2020
Squarepoint Ops LLC bought a new position in shares of AxoGen, Inc (NASDAQ:AXGN) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor bought 19,232 shar
AxoGen (NASDAQ:AXGN) Trading 26.9% Higher
06:32am, Friday, 03'rd Jul 2020
AxoGen, Inc (NASDAQ:AXGN)’s stock price traded up 26.9% on Wednesday . The company traded as high as $12.72 and last traded at $11.73, 4,252,326 shares traded hands during trading. An increase of 74
Canaccord Genuity Downgrades AxoGen (AXGN) to Hold - Markets
10:01am, Thursday, 02'nd Jul 2020
Canaccord Genuity analyst Kyle Rose downgraded AxoGen (AXGN – Research Report) to Hold yesterday and set a price target of
Analyst Explains Why They Downgraded Their Rating on AxoGen (AXGN) - Markets
02:25pm, Wednesday, 01'st Jul 2020
AxoGen (AXGN – Research Report) received a Hold rating from BTIG analyst Ryan Zimmerman today. The company’s shares closed last
Axogen Announces New Seven-Year Financing Agreement with Oberland Capital and Provides Preliminary Second Quarter Revenue Estimate
11:00am, Wednesday, 01'st Jul 2020
Axogen, Inc. (AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced a financing agreement with Oberland Capital and provided p
Head-To-Head Analysis: AxoGen (NASDAQ:AXGN) versus Natus Medical (NASDAQ:NTUS)
01:36am, Friday, 26'th Jun 2020
AxoGen (NASDAQ:AXGN) and Natus Medical (NASDAQ:NTUS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings,
